Englewood, Colorado-based biopharmaceutical firm, Ampio Pharmaceuticals, Inc., has announced its continued pursuit of developing treatments for pain related to osteoarthritis. Specifically, the company is directing its efforts toward the preclinical development of a proprietary small molecule formulation, AR-300, which targets osteoarthritis of the knee.